Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA
This guidance provides EU/EEA countries with the latest scientific evidence to help develop, implement, improve, monitor and evaluate national or local HIV, HBV and HCV testing guidelines and programmes. It offers a range of evidence-based options for the design of testing interventions in different settings and populations and supports the variation and integration of testing services.
This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance
The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe.
Increasing testing coverage and uptake, especially for those most at risk, is an essential element of any strategy to eliminate HIV, HBV and HCV in the European Union and European Economic Area (EU/EEA). In order to interrupt existing transmission chains and prevent further infections, Europe needs a stronger focus on working closely with vulnerable populations. This will improve efforts to identify those who are infected but not diagnosed and link them to appropriate healthcare services.
Read the full report
Public health guidance on HIV, hepatitis B and C testing in the EU/EEA
This guidance aims to provide EU/EEA countries with an evidence-based framework to help develop, implement, monitor and evaluate their own national HBV, HCV and HIV testing guidelines and programmes.
Read more on the ECDC website
Marking European Testing Week: ECDC issues integrated hepatitis and HIV testing Guidance
To mark European Testing Week from 23 to 30 November 2018, ECDC publishes its new Guidance on integrated viral hepatitis and HIV testing.
World AIDS Day 2018: Know the epidemic, shape the response
1 Dec 2018 to 1 Dec 2018 - The tools to end new HIV infections and AIDS exist. The knowledge on how to use them is agreed upon. Nevertheless late diagnosis of HIV remains a challenges across the European Union and European Economic Area.
Hepatitis B and C testing activities, needs, and priorities in the EU/EEA
30 May 2017 - ECDC undertook a survey to assess needs and priorities prior to developing guidance on testing and screening for hepatitis B and C (HBV/HCV) in the EU/EEA, and to update the existing evidence on the burden of HBV/HCV morbidity and mortality across EU/EEA Member States.
The benefits of HIV treatment: undetectable means you do not pass on the virus
25 Jul 2018 - Since its introduction in the 1990s, the main aim of combination antiretroviral therapy (ART) for HIV has been to halt the progression of the infection, maintaining the health of the HIV-positive person taking treatment. In addition to this, the impact of treatment as prevention has been well described.
All updates on HIV and hepatitis B and C
Pre-exposure prophylaxis in the EU/EEA. PrEP service delivery and monitoring: minimum standards and key principles
Effective use of digital platforms for STI/HIV prevention among MSM in the EU/EEA
This ECDC series provides comprehensive guides to the effective use of digital platforms for STI/HIV prevention among MSM in the EU/EEA. The guides incorporate the expertise of stakeholders, scientific literature relating to social media and digital platforms, commercial sector best practice and engagement with the platform companies themselves.Read more
Public health guidance on HIV and STI prevention among men who have sex with men
17 Jun 2015 - This guidance, based on a systematic review of the literature and expert opinion, suggests that there is good evidence to ensure that some key components are considered for inclusion in national and sub-national public health programmes in countries in Europe.
Public health guidance on prevention and control of blood-borne viruses in prison settings
23 Jul 2018 - This document provides EU/EEA Member States with evidence-based scientific advice on available options, when planning and implementing prevention and control interventions for blood-borne viruses in prison settings.